Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome

Next Previous
X
Search
Trial Profile

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CSL 112 (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders; Myocardial infarction; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms AEGIS-II
  • Sponsors CSL Behring

    • Most Recent Events

    • 16 Feb 2024 According to an ABIONYX Pharma media release, the company intends to clarify that the Phase 3 clinical results for CSL112 are extremely positive for the company's development and future.
    • 16 Feb 2024 Results presented in an ABIONYX Pharma Media Release.
    • 15 Feb 2024 Results published in ABIONYX Pharma Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top